DexCom earnings beat by $0.03, revenue topped estimates
ROSH PINA, ISRAEL - IR-MED Inc. (OTCQB: IRME), a small-cap medical device company currently valued at approximately $6 million, announced interim results from its U.S. clinical study of PressureSafe, a handheld infrared spectroscopy device designed to assess pressure injuries before visible skin breakdown. According to InvestingPro data, analysts expect both sales and net income growth for the company this year.
The preliminary findings, based on 786 scans across 163 anatomical sites at Methodist Healthcare in San Antonio, Texas, showed the device achieved 94% sensitivity in assessing tissue at high risk for Stage 1 pressure injuries and suspected deep tissue injuries before skin breakdown. The study included a significant proportion of participants (61%) with darker skin tones. While the company's stock has seen a significant decline of over 80% year-to-date, analysts maintain a bullish outlook with a $3 price target, according to InvestingPro analysis.
Dr. Mary Lee Potter, Principal Investigator and Wound Care Specialist at HCA Healthcare, said the device offers "a rapid, objective tool to assess tissue risk, especially in patients with dark skin tones."
The interim results were presented at the HCA Healthcare & Galen College of Nursing Research Day in June. Dr. Potter will also present the findings at the 2025 ANCC Magnet/ANE Research Symposium in Atlanta on October 7.
PressureSafe is currently undergoing usability studies at multiple medical centers and is not yet commercially available. The technology aims to address pressure injuries, which account for $26.8 billion in U.S. healthcare spending and result in 60,000 deaths annually, according to the company's press release statement. For investors interested in deeper analysis of IR-MED's potential in this substantial market, InvestingPro offers additional insights through its comprehensive financial health metrics and 5 more exclusive ProTips.
The device is designed to provide assessment capabilities regardless of patient skin tone, potentially addressing disparities in pressure injury detection.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.